WO2009028573A1 - 血液凝固障害におけるリバビリンの利用 - Google Patents

血液凝固障害におけるリバビリンの利用 Download PDF

Info

Publication number
WO2009028573A1
WO2009028573A1 PCT/JP2008/065338 JP2008065338W WO2009028573A1 WO 2009028573 A1 WO2009028573 A1 WO 2009028573A1 JP 2008065338 W JP2008065338 W JP 2008065338W WO 2009028573 A1 WO2009028573 A1 WO 2009028573A1
Authority
WO
WIPO (PCT)
Prior art keywords
ribavirin
blood coagulation
coagulation disorder
condition
pharmaceutical agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/065338
Other languages
English (en)
French (fr)
Inventor
Takashi Honda
Junki Takamatsu
Hidenori Toyoda
Koji Yamamoto
Hidemi Goto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nagoya University
Original Assignee
Nagoya University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nagoya University filed Critical Nagoya University
Priority to EP08828257A priority Critical patent/EP2201953A4/en
Priority to JP2009530160A priority patent/JPWO2009028573A1/ja
Priority to US12/733,396 priority patent/US20110117054A1/en
Publication of WO2009028573A1 publication Critical patent/WO2009028573A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

【課題】プロトロンビン時間が延長する状態又はＩＮＲ（International Normalized Ratio）が上昇する状態を改善等するのに有効な医薬を提供する。 【解決手段】リバビリン又はその誘導体を有効成分とする医薬とする。
PCT/JP2008/065338 2007-08-27 2008-08-27 血液凝固障害におけるリバビリンの利用 Ceased WO2009028573A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08828257A EP2201953A4 (en) 2007-08-27 2008-08-27 USE OF RIBAVIRIN IN BLOOD CLEANING DISORDERS
JP2009530160A JPWO2009028573A1 (ja) 2007-08-27 2008-08-27 血液凝固障害におけるリバビリンの利用
US12/733,396 US20110117054A1 (en) 2007-08-27 2008-08-27 Use of ribavirin in blood coagulation disorder

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007220449 2007-08-27
JP2007-220450 2007-08-27
JP2007-220449 2007-08-27
JP2007220450 2007-08-27

Publications (1)

Publication Number Publication Date
WO2009028573A1 true WO2009028573A1 (ja) 2009-03-05

Family

ID=40387290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/065338 Ceased WO2009028573A1 (ja) 2007-08-27 2008-08-27 血液凝固障害におけるリバビリンの利用

Country Status (4)

Country Link
US (1) US20110117054A1 (ja)
EP (1) EP2201953A4 (ja)
JP (1) JPWO2009028573A1 (ja)
WO (1) WO2009028573A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019116500A (ja) * 2010-07-30 2019-07-18 バクスアルタ インコーポレイテッド オキシム連結のための求核触媒

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5029720A (ja) 1973-03-12 1975-03-25
JPS50154253A (ja) 1974-03-18 1975-12-12
JPS53124271A (en) 1971-06-01 1978-10-30 Icn Pharmaceuticals Process for preparing 1*2*44triazolenucleoside
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4695623A (en) 1982-05-06 1987-09-22 Amgen Consensus human leukocyte interferon
WO1995013090A1 (en) 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
JP2001181204A (ja) 1999-12-24 2001-07-03 Chemo Sero Therapeut Res Inst 血液凝固異常に基づく疾患の治療・予防用医薬組成物
JP2002527522A (ja) 1998-10-16 2002-08-27 シェリング・コーポレーション 慢性Ｃ型肝炎感染を有する患者における検出可能ＨＣＶ−ＲＮＡ根絶用リバビリン−インターフェロン−α併用療法
JP2002303624A (ja) * 2001-01-31 2002-10-18 Toyama Chem Co Ltd ガレクチン−３誘導能を利用した物質のスクリーニング方法、肝の状態の診断方法およびこれらの方法を利用したキット
JP2005118005A (ja) * 2003-10-20 2005-05-12 Shinshu Univ 肝臓集積性細胞
JP2007055899A (ja) 2003-10-27 2007-03-08 Chemo Sero Therapeut Res Inst 血液凝固第ｘ因子を主剤とする血液凝固異常に基づく疾患の治療・予防用医薬組成物
WO2007099652A1 (ja) * 2006-02-28 2007-09-07 National University Corporation Nagoya University 血液凝固障害治療用医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029471A1 (en) * 1993-06-10 1994-12-22 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
WO2009028575A1 (ja) * 2007-08-27 2009-03-05 National University Corporation Nagoya University 血液凝固第vii因子プロモーターの活性化剤及びその利用

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53124271A (en) 1971-06-01 1978-10-30 Icn Pharmaceuticals Process for preparing 1*2*44triazolenucleoside
JPS5029720A (ja) 1973-03-12 1975-03-25
JPS50154253A (ja) 1974-03-18 1975-12-12
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4695623A (en) 1982-05-06 1987-09-22 Amgen Consensus human leukocyte interferon
US4897471A (en) 1982-05-06 1990-01-30 Amgen Consensus human leukocyte interferon
WO1995013090A1 (en) 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
JP2002527522A (ja) 1998-10-16 2002-08-27 シェリング・コーポレーション 慢性Ｃ型肝炎感染を有する患者における検出可能ＨＣＶ−ＲＮＡ根絶用リバビリン−インターフェロン−α併用療法
JP2001181204A (ja) 1999-12-24 2001-07-03 Chemo Sero Therapeut Res Inst 血液凝固異常に基づく疾患の治療・予防用医薬組成物
JP2002303624A (ja) * 2001-01-31 2002-10-18 Toyama Chem Co Ltd ガレクチン−３誘導能を利用した物質のスクリーニング方法、肝の状態の診断方法およびこれらの方法を利用したキット
JP2005118005A (ja) * 2003-10-20 2005-05-12 Shinshu Univ 肝臓集積性細胞
JP2007055899A (ja) 2003-10-27 2007-03-08 Chemo Sero Therapeut Res Inst 血液凝固第ｘ因子を主剤とする血液凝固異常に基づく疾患の治療・予防用医薬組成物
WO2007099652A1 (ja) * 2006-02-28 2007-09-07 National University Corporation Nagoya University 血液凝固障害治療用医薬組成物

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ALIMENT. PHARMACOL. THER., vol. 21, no. 1, 1 January 2005 (2005-01-01), pages 49 - 55
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2004 (2004-05-01), pages 1872 - 1875
J. MED. CHEM, vol. 20, 1977, pages 1684 - 1687
J. MED. CHEM., vol. 35, 1992, pages 3231 - 3238
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, vol. 4, pages 469 - 487
KOKAME ET AL., JBC, vol. 276, 2001, pages 9166 - 9205
See also references of EP2201953A4
VIRUS RESEARCH, vol. 107, 2005, pages 165 - 171
YAMAMOTO K. ET AL: "Anti-HCV agent ribavirin elevates the activity of clotting factor VII in patients with hemophilia: a possible mechanism of decreased events of bleeding in patients with hemophilia by ribavirin", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, vol. 4, no. 2, February 2006 (2006-02-01), pages 469 - 470, XP003017333 *
YAMAMOTO K. ET AL: "Ketsuyubyo kanja ni okeru C-gata kan'en chiryoyaku ribavirin no shukketsu yobo koka to sono mechanism", JAPANESE JOURNAL OF THROMBOSIS AND HEMOSTASIS, vol. 16, no. 5, 1 October 2005 (2005-10-01), pages 519, XP003017334 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019116500A (ja) * 2010-07-30 2019-07-18 バクスアルタ インコーポレイテッド オキシム連結のための求核触媒
JP2021038256A (ja) * 2010-07-30 2021-03-11 バクスアルタ インコーポレイテッド オキシム連結のための求核触媒
JP2022046676A (ja) * 2010-07-30 2022-03-23 武田薬品工業株式会社 オキシム連結のための求核触媒
JP7054407B2 (ja) 2010-07-30 2022-04-13 武田薬品工業株式会社 オキシム連結のための求核触媒
JP7258999B2 (ja) 2010-07-30 2023-04-17 武田薬品工業株式会社 オキシム連結のための求核触媒

Also Published As

Publication number Publication date
US20110117054A1 (en) 2011-05-19
EP2201953A4 (en) 2011-08-03
EP2201953A1 (en) 2010-06-30
JPWO2009028573A1 (ja) 2010-12-09

Similar Documents

Publication Publication Date Title
WO2006096439A3 (en) Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2007103719A3 (en) MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2007127158A3 (en) Modification of percutaneous absorption of topically active materials
WO2006096434A3 (en) Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2008087367A3 (fr) Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazodyl)-phenyl-propan-1-one substitues, preparations et utilisations
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2008139122A3 (fr) Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
WO2007125105A3 (en) Benzamide glucokinase activators
UY31765A (es) Dihidropirazolonas sustituidas y su uso
WO2009091550A3 (en) Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
DOP2007000043A (es) Derivados de cromanol sustituidos y su uso
WO2010021607A3 (en) Pharmaceutical formulation
WO2007121125A3 (en) Hcv inhibitors
WO2011095882A8 (en) Combination composition, comprising as active ingredient l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insufficiency
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
WO2011076209A3 (en) Pharmaceutical composition comprising solvent mixture and a vitamin d derivative or analogue
WO2010074936A3 (en) Enzastaurin for the treatment of cancer
WO2009038095A1 (ja) セサミン類とビタミンｂ１類とを配合した組成物
WO2006085115A3 (en) Therapeutic uses of tomato extracts
WO2006020680A3 (en) Heterocyclic compounds as pharmaceutical agents
EP2481428A3 (en) MMP activated vascular disrupting agents
WO2007101106A3 (en) Compositions and methods for modulating hemostasis using variant forms of activated factor v

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08828257

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009530160

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008828257

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12733396

Country of ref document: US